RxDoctor Payments Data

Richard Singer, MD

Neurology · Sunrise, FLNPI 1164474607

Payments from drug & device makers

$556,240in general payments, 2019–2025

Across 358 payments — averaging $1553.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$276K
  • Eli Lilly$119K
  • Acadia Pharmaceuticals Inc$63K
  • Takeda Pharmaceuticals U.S.A., Inc.$54K
  • Amgen$21K
  • Lundbeck LLC$9K
  • plus $14K from 28 others
$2,080in research payments, 2019–2025

Across 11 payments — averaging $189.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Acadia Pharmaceuticals Inc$2K
  • Eli Lilly$100

What the payments were for

  • Consulting fees$15,24336%
  • Speaking & faculty fees$19,85046%
  • Travel & lodging$1,5644%
  • Food & beverage$6,14514%
  • Education$1320%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$556,240 in reported general payments places this provider in the 90th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$45,411
Medicare patients
115
Services billed
2,170

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammakedImmune Globul G/Gly/Iga Avg 4616$386,242
NuplazidPimavanserin Tartrate14$74,825
Emgality PenGalcanezumab-Gnlm41$38,651
NamzaricMemantine Hcl/Donepezil Hcl44$31,316
AptiomEslicarbazepine Acetate12$30,012
BotoxOnabotulinumtoxina16$26,964
VimpatLacosamide13$26,812
UbrelvyUbrogepant14$23,150
FycompaPerampanel11$13,214
Lacosamide40$4,853
Rasagiline Mesylate32$4,414
Carbidopa-LevodopaCarbidopa/Levodopa212$3,298
Levetiracetam119$3,080
Dimethyl Fumarate17$2,820
Memantine Hcl177$2,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieNamzaric, Botox, Ubrelvy$1,375$81,43074 claims
Acadia Pharmaceuticals IncNuplazid$62,953$74,82514 claims
Sunovion Pharmaceuticals Inc.Aptiom$109$30,01212 claims
Eisai Inc.Fycompa$276,446$13,21411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,434 neurology providers in Florida.

Other neurology in Sunrise

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →